Study: Rushing FDA approvals might compromise drug safety

Harvard University researchers found drugs the FDA cleared shortly before its deadline are more prone to safety problems than those approved with time to spare. The FDA said it does not grant approval unless it is ready. It "has the option of denying approval altogether if there is any question about safety," said Janet Woodcock, head of the agency's Center for Drug Evaluation and Research.

View Full Article in:

Wall Street Journal (free content), The · Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD